NF- B and IKK as Key Mediators of Inflammation and Oncogenic Progression

Interstitial lung disease, a term for a group of disorders, causes lung fibrosis, is mostly refractory to treatments and has a high death rate. After diagnosis the survival is up to 3 years but in some cases the patients live much longer. It involves a heterogenous group of lung diseases that exhibit progressive and irreversible destruction of the lung due to the formation of scars. This results in lung malfunction, disruption of gas exchange, and eventual death because of respiratory failure. The etiology of lung fibrosis is mostly unknown with a few exceptions. The major characteristics of the disease are comprised of injury of epithelial type II cells, increased apoptosis, chronic inflammation, monocytic and lymphocytic infiltration, accumulation of myofibroblasts, and inability to repair damaged tissue properly. These events result in abnormal collagen deposition and scarring. The inflammation process is mild, and the disease is primarily fibrotic driven. Immunosuppressants do not treat the disease but the evidence is evolving that both innate and acquired immune responses a well as the cytokines contribute to at least early progression of the disease. Furthermore, mediators of inflammation including cytokines are involved throughout the process of lung fibrosis. The diverse clinical outcome of the disease is due to different pattern of inflammatory markers. Nonetheless, the development of novel therapeutic strategies requires better understanding of the role of the immune response. This review highlights the role of the immune response in interstitial lung disease and considers the therapeutic strategies based on these observations. For this review several literature data sources were used to assess the role of the immune response in interstitial lung disease and to evaluate the possible therapeutic strategies for the disease.

Download Full-text

The Role of Leukotrienes Inhibitors in the Management of Chronic Inflammatory Diseases

Recent Patents on Inflammation & Allergy Drug Discovery ◽

10.2174/1872213x14666200130095040 ◽

2020 ◽

Vol 14 (1) ◽

pp. 15-31

Author(s):

Deepak Meshram ◽

Khushbo Bhardwaj ◽

Charulata Rathod ◽

Gail B. Mahady ◽

Kapil K. Soni

Keyword(s):

Respiratory Diseases ◽

Inflammatory Diseases ◽

Leukotriene B4 ◽

Published Data ◽

Free Text ◽

Plant Origin ◽

Medical Subject Headings ◽

Leukotriene Antagonists ◽

Mesh Terms ◽

Mediators Of Inflammation

Background: Leukotrienes are powerful mediators of inflammation and interact with specific receptors in target cell membrane to initiate an inflammatory response. Thus, Leukotrienes (LTs) are considered to be potent mediators of inflammatory diseases including allergic rhinitis, inflammatory bowel disease and asthma. Leukotriene B4 and the series of cysteinyl leukotrienes (C4, D4, and E4) are metabolites of arachidonic acid metabolism that cause inflammation. The cysteinyl LTs are known to increase vascular permeability, bronco-constriction and mucus secretion. Objectives: To review the published data for leukotriene inhibitors of plant origin and the recent patents for leukotriene inhibitors, as well as their role in the management of inflammatory diseases. Methods: Published data for leukotrienes antagonists of plant origin were searched from 1938 to 2019, without language restrictions using relevant keywords in both free text and Medical Subject Headings (MeSH terms) format. Literature and patent searches in the field of leukotriene inhibitors were carried out by using numerous scientific databases including Science Direct, PubMed, MEDLINE, Google Patents, US Patents, US Patent Applications, Abstract of Japan, German Patents, European Patents, WIPO and NAPRALERT. Finally, data from these information resources were analyzed and reported in the present study. Results: Currently, numerous anti-histaminic medicines are available including chloropheneremine, brompheniramine, cetirizine, and clementine. Furthermore, specific leukotriene antagonists from allopathic medicines are also available including zileuton, montelukast, pranlukast and zafirlukast and are considered effective and safe medicines as compared to the first generation medicines. The present study reports leukotrienes antagonistic agents of natural products and certain recent patents that could be an alternative medicine in the management of inflammation in respiratory diseases. Conclusion: The present study highlights recent updates on the pharmacology and patents on leukotriene antagonists in the management of inflammation respiratory diseases.

Download Full-text

Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury

Current Molecular Pharmacology ◽

10.2174/1874467213666201223111743 ◽

2020 ◽

Vol 13 ◽

Author(s):

Ashif Iqubal ◽

Musheer Ahmed ◽

Mohammad Kashif Iqubal ◽

Faheem Hyder Pottoo ◽

Syed Ehtaishamul Haque

Keyword(s):

Spinal Cord ◽

Spinal Cord Injury ◽

Side Effects ◽

Transient Receptor Potential ◽

Receptor Potential ◽

Neutrophil Infiltration ◽

Matrix Metal ◽

Mediators Of Inflammation ◽

Major Player ◽

Cord Injury

: Spinal cord injury (SCI) and associated pain and inflammation caused by the trauma or infection is one of the serious health care issues world-wide. The various inflammatory, redox-sensitive and apoptotic events are contributing factor but altered neuronal function, axonal degeneration, activated microglia, endothelial cells, astrocytes, fibroblasts,pericytes, Schwann cells, meningeal cells are the major player in its pathogenesis. Further, monocytes and neutrophil infiltration get recruited and facilitate the release of chemokines, cytokines, and other mediators of inflammation. This event leads to the production of different amino acids, neuropeptides kinin, prostaglandins, prostacyclin, thromboxane, leukotrienes, bradykinin, histamine, matrix metal proteinases and serotonin that stimulate nerve endings and manifests the inflammation and pain processes, etc. Arachidonic acid (AA), NF-kB, NLRP3 inflammasome, and nitric oxide pathways along with P2X7 receptor and ion channel transient receptor potential (TRP) vanilloid are some of the recently explored targets for modulation of pain and inflammation in SCI. Till now, NSAIDs, opioids, antidepressants, anticonvulsants, NMDA antagonists, α2-adrenergic agonists, and GABA-receptor agonists are used for the management of these pathological conditions. However, these drugs are associated with various side effects. Additionally, the number of available animal models for SCI has enhanced the understanding of the complex pathological mechanisms involved in the generation of chronic inflammatory pain in SCI. These findings enable us to identify and validate several potent natural analgesic-anti-inflammatory drug candidates with minimal side effects. However, until now, these compounds have been studied in preclinical models and shown promising results but no clinical studies have been performed. Therefore, a detailed exploration of these natural compounds is important for bringing them from bench to bedside.

Download Full-text

Endocannabinoids

10.1093/oso/9780190846848.003.0004 ◽

2018 ◽

Author(s):

Leslie Iversen

Keyword(s):

Arachidonic Acid ◽

Energy Metabolism ◽

Pain Sensitivity ◽

Large Family ◽

Cardiovascular Control ◽

Lipid Signaling ◽

Physiological Functions ◽

Functional Roles ◽

Metabolism Regulation ◽

Mediators Of Inflammation

The endocannabinoids are part of a large family of lipid signaling molecules derived from arachidonic acid, including the prostaglandins and leukotrienes, which are important mediators of inflammation. Far less is known about the newer members of the endocannabinoid group, and it remains unclear whether they all play important functional roles. This chapter reviews the multiple members of this family and their biosynthesis and inactivation. Physiological functions, including retrograde synaptic signaling, control of energy metabolism, regulation of pain sensitivity, and cardiovascular control, are discussed. In addition, the chapter reports the synthesis of novel agonists, antagonists, and compounds inhibiting endocannabinoid inactivation as novel medicines.

Download Full-text

Lactobacillus acidophilus ATCC 4356 Exopolysaccharides Suppresses Mediators of Inflammation through the Inhibition of TLR2/STAT-3/P38-MAPK Pathway in DEN-Induced Hepatocarcinogenesis in Rats

Nutrition and Cancer ◽

10.1080/01635581.2021.1934490 ◽

2021 ◽

pp. 1-11

Author(s):

Ola M. S. Khedr ◽

Sawsan M. El-Sonbaty ◽

Fatma S. M. Moawed ◽

Eman I. Kandil ◽

Basma E. Abdel-Maksoud

Keyword(s):

P38 Mapk ◽

Lactobacillus Acidophilus ◽

Mapk Pathway ◽

P38 Mapk Pathway ◽

Mediators Of Inflammation

Download Full-text

Regulation of TREM1-Mediated Inflammation in Hepatocellular Carcinoma Cells

Reports ◽

10.3390/reports4020017 ◽

2021 ◽

Vol 4 (2) ◽

pp. 17

Author(s):

Vikrant Rai ◽

Devendra K. Agrawal

Keyword(s):

Hepatocellular Carcinoma ◽

Vitamin D ◽

Chronic Inflammation ◽

Therapeutic Target ◽

Primary Liver Cancer ◽

Migration And Invasion ◽

Potential Therapeutic Target ◽

Mediators Of Inflammation ◽

Tnf Α ◽

Hcc Cells

Hepatocellular carcinoma (HCC), accounting for more than 90% of cases of primary liver cancer, is the third most common cause of cancer-related death worldwide. Chronic inflammation precedes the development of cirrhosis and HCC. TREM (triggering receptor expressed on myeloid cell)-1 is an inflammatory marker and amplifier of inflammation that signals through PI3K and ERK1/2 to activate transcription factors, resulting in increased secretion of pro-inflammatory cytokines, causing chronic inflammation and predisposing the liver to carcinogenesis. Thus, targeting TREM-1 in HCC might be a potential therapeutic target. A low level of vitamin D has been associated with chronic inflammation and poor prognosis in HCC. Thus, we evaluated the effect of vitamin D on TREM-1 expression in the HCC cell line. Additionally, the effects of high mobility group box-1, lipopolysaccharide, and transcription factor PU.1 on the expression of TREM-1 in normal liver cells and HCC cells have been investigated in the presence and absence of vitamin D. The results showed increased expression of TREM-1 in HCC cells and with IL-6, TNF-α, LPS, and rHMGB-1 and decreased expression with calcitriol. Calcitriol also attenuated the effect of IL-6, TNF-α, LPS, and rHMGB-1 on TREM-1. Calcitriol treatment attenuated the proliferation, migration, and invasion of HCC cells. These results (in vitro) provide molecular and biochemical evidence that calcitriol significantly attenuates the expression of mediators of inflammation, and thus might be used therapeutically together with conventional treatment to delay the progression of HCC. Additionally, the negative regulation of TREM-1 by PU.1 suggests PU.1 as a potential therapeutic target.

Download Full-text